SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia
Globe Newswire•28/10/2026•08:35 ET
0
Key Highlights
- ➤REGAL reaches its pre-specified 80th death event, triggering final analysis
- ➤SELLAS will report topline primary endpoint results this quarter
- ➤GPS is being evaluated as maintenance therapy for AML patients in second remission
Expert Statements
Angelos Stergiou, President and Chief Executive Officer of SELLAS
“Reaching the 80th event represents a critical milestone in the REGAL trial”
Angelos Stergiou, President and Chief Executive Officer of SELLAS
“AML remains an area of significant unmet need, particularly for patients in second complete remission with limited treatment options.”
Angelos Stergiou, President and Chief Executive Officer of SELLAS
“With this pivotal study now advancing to final analysis, we look forward to evaluating the data, as positive results could position GPS as the first- and best-in-class novel immunotherapeutic option for these patients.”
Angelos Stergiou, President and Chief Executive Officer of SELLAS
“On behalf of everyone at SELLAS, my sincerest appreciation goes out to all the physicians, nurses, study teams and, importantly, the participating patients and their families for their immense contributions in advancing the REGAL study.”
Angelos Stergiou, President and Chief Executive Officer of SELLAS
“Our commitment to delivering hope to the AML community has never been stronger.”
- Reaching the Pre-Specified 80(th) Event Triggers the Final Analysis of the Pivotal Phase 3 Trial -
Company to Report Topline Primary Endpoint Results this Quarter -
Get started
Create a free account to read the full story.